Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03168438
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: avelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab paclitaxelBiological: nivolumabDrug: LovazaDrug: OxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169738
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
- Conditions
- Malignant Melanoma Stage IV
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03166397
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
- Conditions
- Merkel Cell Carcinoma
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-fluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: omega-3-acid ethyl estersRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-051Biological: ETBX-061Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167164
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
- Conditions
- Melanoma
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-fluorouracilDrug: LeucovorinDrug: nab-paclitaxelBiological: NivolumabDrug: omega-3-acid ethyl estersRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167177
Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer
- Conditions
- Cancer, BreastTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT03164993
- Locations
- 🇩🇰
Vejle Sygehus, Vejle, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇳🇴Oslo University Hospital, Oslo, Norway
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: CyclophosphamideDrug: NivolumabDrug: GVAX Pancreas VaccineRadiation: Stereotactic Body Radiation (SBRT)
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 28
- Registration Number
- NCT03161379
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
- Conditions
- Aggressive Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 21
- Registration Number
- NCT03161054
- Locations
- 🇮🇹
A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
🇮🇹Ospedale di Castelfranco Veneto - Ematologia, Castelfranco Veneto, Italy
🇮🇹Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS c/o CORE (II piano) - Ematologia, Reggio Emilia, Italy
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
- Conditions
- Advanced Ovarian CancerMalignant Melanoma
- Interventions
- Drug: CyclophosphamideDrug: FludarabineProcedure: PembrolizumabBiological: Tumor-Infiltrating Lymphocytes (TILs)Biological: Interleukin-2 (IL-2)
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 8
- Registration Number
- NCT03158935
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
- Conditions
- OligodendrogliomaGangliogliomaGlioblastomaPylocytic/Pylomyxoid AstrocytomaBrain TumorGliomaMalignant Glioma of BrainAstrocytomaMalignant AstrocytomaMixed Oligo-Astrocytoma
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT03152318
- Locations
- 🇺🇸
Johns Hopkins University Medical Center, Baltimore, Maryland, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.